1. García-Prieto A, de la Flor JC, Coll E, Iglesias E, Reque J, Valga F. Expanded hemodialysis: what's up, Doc? Clin Kidney J 2023;16:1071–1080.

2. Zhu L, Liu F, Yu X, Xue L. Poly(lactic acid) hemodialysis membranes with poly(lactic acid)-block-poly(2-hydroxyethyl methacrylate) copolymer as additive: preparation, characterization, and performance. ACS Appl Mater Interfaces 2015;7:17748–17755.

3. Palmer SC, Rabindranath KS, Craig JC, Roderick PJ, Locatelli F, Strippoli GF. High-flux versus low-flux membranes for end-stage kidney disease. Cochrane Database Syst Rev 2012;2012:CD005016.

4. Ward RA. Protein-leaking membranes for hemodialysis: a new class of membranes in search of an application? J Am Soc Nephrol 2005;16:2421–2430.

5. Vanholder R, De Smet R, Glorieux G, et al.; European Uremic Toxin Work Group (EUTox). Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003;63:1934–1943.

6. Wolley M, Jardine M, Hutchison CA. Exploring the clinical relevance of providing increased removal of large middle molecules. Clin J Am Soc Nephrol 2018;13:805–814.

7. Rosner MH, Reis T, Husain-Syed F, et al. Classification of uremic toxins and their role in kidney failure. Clin J Am Soc Nephrol 2021;16:1918–1928.

8. Gondouin B, Hutchison CA. High cut-off dialysis membranes: current uses and future potential. Adv Chronic Kidney Dis 2011;18:180–187.

9. Boschetti-de-Fierro A, Voigt M, Storr M, Krause B. MCO membranes: enhanced selectivity in high-flux class. Sci Rep 2015;5:18448.

10. Yang JW. What is the final destination of hemodialysis membrane? Kidney Res Clin Pract 2024;43:700–702.

11. Macías N, Vega A, Abad S, et al. Middle molecule elimination in expanded haemodialysis: only convective transport? Clin Kidney J 2018;12:447–455.

12. Lorenzin A, Neri M, Lupi A, et al. Quantification of internal filtration in hollow fiber hemodialyzers with medium cut-off membrane. Blood Purif 2018;46:196–204.

13. Maduell F, Broseta JJ, Rodríguez-Espinosa D, et al. Comparison of four medium cut-off dialyzers. Clin Kidney J 2022;15:2292–2299.

14. García-Prieto A, Vega A, Linares T, et al. Evaluation of the efficacy of a medium cut-off dialyser and comparison with other high-flux dialysers in conventional haemodialysis and online haemodiafiltration. Clin Kidney J 2018;11:742–746.

15. Reque J, Pérez Alba A, Panizo N, Sánchez-Canel JJ, Pascual MJ, Pons Prades R. Is expanded hemodialysis an option to online hemodiafiltration for small- and middle-sized molecules clearance? Blood Purif 2019;47:126–131.

16. Kirsch AH, Lyko R, Nilsson LG, et al. Performance of hemodialysis with novel medium cut-off dialyzers. Nephrol Dial Transplant 2017;32:165–172.

17. Bunch A, Sanchez R, Nilsson LG, et al.; Colombian Registry of Expanded Hemodialysis investigators. Medium cut-off dialyzers in a large population of hemodialysis patients in Colombia: COREXH registry. Ther Apher Dial 2021;25:33–43.

18. Kim CS, Joo SY, Choi HS, Bae EH, Ma SK, Kim SW. Comparison of the medium cut-off dialyzer and postdilution hemodiafiltration on the removal of small and middle molecule uremic toxins. Kidney Res Clin Pract 2023;42:712–722.

19. Cho NJ, Park S, Islam MI, Song HY, Lee EY, Gil HW. Long-term effect of medium cut-off dialyzer on middle uremic toxins and cell-free hemoglobin. PLoS One 2019;14:e0220448.

20. Kim YG, Lee SH, Jung SW, et al. The medium cut-off membrane does not lower protein-bound uremic toxins. Toxins (Basel) 2022;14:779.

21. Cho NJ, Jeong SH, Lee KY, et al. Clinical safety of expanded hemodialysis compared with hemodialysis using high-flux dialyzer during a three-year cohort. J Clin Med 2022;11:2261.

22. Caravaca F, Arrobas M, Dominguez C. Serum albumin and other serum protein fractions in stable patients on peritoneal dialysis. Perit Dial Int 2000;20:703–707.

23. Kim TH, Kim SH, Kim TY, et al. Removal of large middle molecules via haemodialysis with medium cut-off membranes at lower blood flow rates: an observational prospective study. BMC Nephrol 2019;21:2.

24. Hung YH, Lai TS, Belmouaz M, et al. Effects of medium cut-off polyarylethersulfone and polyvinylpyrrolidone blend membrane dialyzers in hemodialysis patients: a systematic review and meta-analysis of randomized controlled trials. Membranes (Basel) 2022;12:443.

25. Yang J, Ke G, Liao Y, Guo Y, Gao X. Efficacy of medium cut-off dialyzers and comparison with high-flux dialyzers in patients on maintenance hemodialysis: a systematic review and meta-analysis. Ther Apher Dial 2022;26:756–768.

26. Kandi M, Brignardello-Petersen R, Couban R, Wu C, Nesrallah G. Effects of medium cut-off versus high-flux hemodialysis membranes on biomarkers: a systematic review and meta-analysis. Can J Kidney Health Dis 2022;9:20543581211067090.

27. Stenvinkel P, Ketteler M, Johnson RJ, et al. IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia--the good, the bad, and the ugly. Kidney Int 2005;67:1216–1233.

28. Chung TL, Liu YH, Wu PY, et al. Blood osteoprotegerin is associated with arteriovenous access thrombosis in hemodialysis patients. Kidney Res Clin Pract 2024 Oct 25 [Epub]. DOI:10.23876/j.krcp.24.153.

29. Kim J, Song SH, Oh TR, et al. Prognostic role of the neutrophil-to-lymphocyte ratio in patients with chronic kidney disease. Korean J Intern Med 2023;38:725–733.

30. Lee YH. Reassessing the role of the neutrophil-to-lymphocyte ratio in chronic kidney disease patients. Korean J Intern Med 2023;38:579–580.

31. Kim HJ, Seong EY, Song SH. Medium cut-off dialyzer improves reduction ratios of large middle molecules associated with vascular calcification. Kidney Res Clin Pract 2024;43:753–762.

32. Ahn SH, Ko MM, Song JH, Jung JH. Changes in plasma sclerostin level associated with use of a medium cut-off dialyzer in end-stage renal disease. Kidney Res Clin Pract 2021;40:120–134.

33. Lim JH, Park Y, Yook JM, et al. Randomized controlled trial of medium cut-off versus high-flux dialyzers on quality of life outcomes in maintenance hemodialysis patients. Sci Rep 2020;10:7780.

34. Alarcon JC, Bunch A, Ardila F, et al.; Colombian Registry of Expanded Hemodialysis Investigators. Impact of medium cut-off dialyzers on patient-reported outcomes: COREXH registry. Blood Purif 2021;50:110–118.

35. Penny JD, Jarosz P, Salerno FR, Lemoine S, McIntyre CW. Impact of expanded hemodialysis using medium cut-off dialyzer on quality of life: application of dynamic patient-reported outcome measurement tool. Kidney Med 2021;3:992–1002.e1.

36. Bolton S, Gair R, Nilsson LG, Matthews M, Stewart L, Mc-Cullagh N. Clinical assessment of dialysis recovery time and symptom burden: impact of switching hemodialysis therapy mode. Patient Relat Outcome Meas 2021;12:315–321.

37. Lee Y, Jang MJ, Jeon J, et al. Cardiovascular risk comparison between expanded hemodialysis using theranova and online hemodiafiltration (CARTOON): a multicenter randomized controlled trial. Sci Rep 2021;11:10807.

38. Lim JH, Jeon Y, Yook JM, et al. Medium cut-off dialyzer improves erythropoiesis stimulating agent resistance in a hepcidin-independent manner in maintenance hemodialysis patients: results from a randomized controlled trial. Sci Rep 2020;10:16062.

39. Yeter HH, Korucu B, Akcay OF, Derici K, Derici U, Arinsoy T. Effects of medium cut-off dialysis membranes on inflammation and oxidative stress in patients on maintenance hemodialysis. Int Urol Nephrol 2020;52:1779–1789.

40. Belmouaz M, Bauwens M, Hauet T, et al. Comparison of the removal of uraemic toxins with medium cut-off and high-flux dialysers: a randomized clinical trial. Nephrol Dial Transplant 2020;35:328–335.

41. Kim B, Park CI, Hong YA, et al. Mortality in patients receiving renal replacement therapy in South Korea. Kidney Res Clin Pract 2024 Jul 24 [Epub]. DOI:10.23876/j.krcp.24.035.

42. Ryou S, Yoon HE. The current state of life expectancy of hemodialysis patients in Korea. Kidney Res Clin Pract 2024;43:562–564.

43. Kim KM, Jeong SA, Ban TH, et al. Status and trends in epidemiologic characteristics of diabetic end-stage renal disease: an analysis of the 2021 Korean Renal Data System. Kidney Res Clin Pract 2024;43:20–32.

44. Huang YC, Wu CK. Effect of the geometry and severity of left ventricular hypertrophy on cardiovascular mortality in dialysis patients. Kidney Res Clin Pract 2024 Sep 11 [Epub]. DOI:10.23876/j.krcp.23.290.

45. Ozarli I, Yeter HH, Sener YZ, Cebrailov C, Yildirim T, Yilmaz R. Effects of a medium cut-off dialyzer on inflammation and cardiac and vascular function in hemodialysis patients with heart failure. Hemodial Int 2024;28:326–335.

46. Molano AP, Hutchison CA, Sanchez R, et al. Medium cut-off versus high-flux hemodialysis membranes and clinical outcomes: a cohort study using inverse probability treatment weighting. Kidney Med 2022;4:100431.

47. de Sequera P, Pérez-García R, Vega A, et al.; MOTheR collaborative network. Trial design of the MOTheR HDx study: a multicenter, open-label, prospective, randomized study to explore the morbidity and mortality in patients dialyzed with the Theranova HDx in comparison with online hemodiafiltration. Clin Kidney J 2023;16:2254–2261.

48. Sanabria RM, Hutchison CA, Vesga JI, Ariza JG, Sanchez R, Suarez AM. Expanded hemodialysis and its effects on hospitalizations and medication usage: a cohort study. Nephron 2021;145:179–187.

49. Blackowicz MJ, Falzon L, Beck W, Tran H, Weiner DE. Economic evaluation of expanded hemodialysis with the Theranova 400 dialyzer: a post hoc evaluation of a randomized clinical trial in the United States. Hemodial Int 2022;26:449–455.

50. Dubin RF, Rhee EP. Proteomics and metabolomics in kidney disease, including insights into etiology, treatment, and prevention. Clin J Am Soc Nephrol 2020;15:404–411.

51. Kim HJ, Song SH. Steps to understanding diabetes kidney disease: a focus on metabolomics. Korean J Intern Med 2024;39:898–905.

52. Kim HJ, Seong EY, Lee W, et al. Comparative analysis of therapeutic effects between medium cut-off and high flux dialyzers using metabolomics and proteomics: exploratory, prospective study in hemodialysis. Sci Rep 2021;11:17335.

53. Hulko M, Kunz M, Yildirim M, Homeyer S, Amon O, Krause B. Cell-free plasma hemoglobin removal by dialyzers with various permeability profiles. Sci Rep 2015;5:16367.

54. Lim JH, Seo YJ, Jeon Y, et al. Expanded hemodialysis with theranova dialyzer and residual kidney function in patients starting long-term hemodialysis: a randomized controlled trial. J Am Soc Nephrol 2025 Mar 4 [Epub]. DOI:10.1681/ASN.0000000655. 55. Canaud B, Gagel A, Peters A, Maierhofer A, Stuard S. Does online high-volume hemodiafiltration offer greater efficiency and sustainability compared with high-flux hemodialysis? A detailed simulation analysis anchored in real-world data. Clin Kidney J 2024;17:sfae147.

56. Zhang Z, Yang T, Li Y, et al. Effects of expanded hemodialysis with medium cut-off membranes on maintenance hemodialysis patients: a review. Membranes (Basel) 2022;12:253.

57. Gauly A, Fleck N, Kircelli F. Advanced hemodialysis equipment for more eco-friendly dialysis. Int Urol Nephrol 2022;54:1059–1065.

58. Agar JW. Green dialysis: the environmental challenges ahead. Semin Dial 2015;28:186–192.

59. Vega-Vega O, Caballero-Islas AE, Del Toro-Cisneros N, et al. Improved β2-microglobulin and phosphorous removal with expanded hemodialysis and online hemodiafiltration versus high-flux hemodialysis: a cross-over randomized clinical trial. Blood Purif 2023;52:712–720.

60. Kim DW, Song SH. Sarcopenia in chronic kidney disease: from bench to bedside. Korean J Intern Med 2023;38:303–321.

61. Ariza JG, Walton SM, Suarez AM, Sanabria M, Vesga JI. An initial evaluation of expanded hemodialysis on hospitalizations, drug utilization, costs, and patient utility in Colombia. Ther Apher Dial 2021;25:621–627.